Cargando…

EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients

INTRODUCTION: The assessment of risk of recurrence and progression of bladder cancer (BC) is still rather difficult. We decided to check the rates of the changes mentioned above in the group of the Polish patients after a year–long observation and next to compare them with the results calculated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borkowska, Edyta M., Jędrzejczyk, Adam, Marks, Piotr, Catto, James W.F., Kałużewski, Bogdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Urological Association 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921849/ https://www.ncbi.nlm.nih.gov/pubmed/24578979 http://dx.doi.org/10.5173/ceju.2013.01.art5

Ejemplares similares

Artificial neural network in predicting bladder cancer recurrence
por: Borkowska, Edyta, et al.
Publicado: (2012)

Detection of loss of heterozygosity in patients with urinary bladder carcinoma: neoplastic tissue vs. urine sediment cells
por: Traczyk, Magdalena, et al.
Publicado: (2011)

The value of EORTC risk tables in evaluating recurrent non–muscle–invasive bladder cancer in everyday practice
por: Walczak, Rafał, et al.
Publicado: (2013)

Polymorphic variants of H-RAS protooncogene and their possible role in bladder cancer etiology
por: Traczyk, Magdalena, et al.
Publicado: (2012)

Significance of CDKN2A gene A148T variant in patients with bladder cancer
por: Borkowska, Edyta, et al.
Publicado: (2011)

Molecular subtyping of bladder cancer using Kohonen self-organizing maps
por: Borkowska, Edyta M, et al.
Publicado: (2014)

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
por: Xylinas, E, et al.
Publicado: (2013)

The A148T variant of CDKN2A gene in bladder cancer
por: Borkowska, E, et al.
Publicado: (2011)

The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation
por: Seo, Kyung Won, et al.
Publicado: (2010)

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
por: Wang, Hui, et al.
Publicado: (2018)

The prevalence of CHEK2 and CYP1B1 mutations/polymorphisms in urinary bladder cancer
por: Banaszkiewicz, Monika, et al.
Publicado: (2012)

Concomitance of oncogenic HPV types, CHEK2 gene mutations, and CYP1B1 gene polymorphism as an increased risk factor for malignancy
por: Banaszkiewicz, Monika, et al.
Publicado: (2013)

Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort
por: Pillai, Rajiv, et al.
Publicado: (2011)

Predicting Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer in Korean Patients: A Comparison of the EORTC and CUETO Models
por: Choi, Se Young, et al.
Publicado: (2014)

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score
por: Simon, Marie, et al.
Publicado: (2019)

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
por: Almeida, Gilberto L., et al.
Publicado: (2016)

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
por: Piao, Xuan-Mei, et al.
Publicado: (2022)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System
por: Shadpour, Pejman, et al.
Publicado: (2016)

Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
por: Ripping, Theodora M., et al.
Publicado: (2021)

The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer
por: Vrieling, Alina
Publicado: (2018)

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
por: Alkhateeb, Sultan S., et al.
Publicado: (2011)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic
por: Panebianco, Valeria, et al.
Publicado: (2020)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

The role of selected egzo- and endogenic agents on preinitiation process of bladder cancer
por: Iwaniuk, A, et al.
Publicado: (2015)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

Non-muscle invasive bladder cancer risk stratification
por: Isharwal, Sumit, et al.
Publicado: (2015)

Adherence to the WCRF/AICR Cancer Prevention Recommendations and Risk of Recurrence in Non-muscle Invasive Bladder Cancer
por: van Zutphen, Moniek, et al.
Publicado: (2022)

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer
por: Ripping, T. M., et al.
Publicado: (2022)

Pilot Testing and Preliminary Psychometric Validation of the Polish Translation of the EORTC INFO25 Questionnaire: Validation of the Polish version of INFO25—pilot study
por: Püsküllüoğlu, Mirosława, et al.
Publicado: (2013)

Knowledge, Behaviors, and Attitudes of Polish Nurses As Compared With Evidence-Based Practice in Relation to the Guidelines of the European Resuscitation Council
por: Ozga, Dorota, et al.
Publicado: (2019)

Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours
por: Vedder, Moniek M., et al.
Publicado: (2014)

Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia
por: Ieda, Takeshi, et al.
Publicado: (2016)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Previous Bladder Cancer History in Patients with High-Risk, Non–muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
por: Mitrakas, Lampros P., et al.
Publicado: (2015)

Risk Factors of Metabolic Syndrome among Polish Nurses
por: Bartosiewicz, Anna, et al.
Publicado: (2021)

The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis
por: Ślusarczyk, Aleksander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sttpa4o2mqsd81dfal6argkh19